Allogeneic Stem Cell Transplantation with CD34+ Cell Selection

Elisa Roldan, Miguel Angel Perales, Pere Barba, Elisa Roldan, Miguel Angel Perales, Pere Barba

Abstract

The success of allogeneic stem cell transplant is hampered by the development of acute and chronic graft-versus-host disease (GvHD) which has direct impact on treatment-related mortality and morbidity. As a result, T cell depletion through positive selection of CD34+ cells has emerged as a promising strategy to reduce acute and chronic GvHD in these patients. In this review, we summarize the main characteristics of allogeneic stem cell transplant with CD34+ cell selection including risks of graft failure, GvHD, infection, organ toxicity, and long-term survival. Moreover, we highlight future strategies to improve the results of this platform and to consolidate its use in clinical practice.

Keywords: Allogeneic transplant; CD34+ cell selection; Graft-versus-host disease; Graft-versus-host disease-free and relapse-free survival (GRFS); T cell depletion.

Conflict of interest statement

M.-A.P. declares have received honoraries from Abbvie, Incyte, Medigene, Merck, MolMed, Nektar Therapeutics, Novartis, Servier and Takeda, not related with the present article. P.B. declares have received honoraries from Amgen, Celgene, Gilead, Incyte, Jazz Pharmaceuticals, MSD, Novartis, Pfizer and Roche, not related with the present article. E.R. declares no conflicting interests.

© 2019 International Academy for Clinical Hematology. Publishing services by Atlantis Press International B.V.

References

    1. Jim HS, Barata A, Small BJ, Jacobsen PB, Pidala J. Quality of life associated with sirolimus for prevention of graft-versus-host disease: results from a randomized trial. Haematologica. 2014;99:548–53. doi: 10.3324/haematol.2013.088781.
    1. Inamoto Y, Flowers ME, Appelbaum FR, et al. A retrospective comparison of tacrolimus versus cyclosporine with methotrexate for immunosuppression after allogeneic hematopoietic cell transplantation with mobilized blood cells. Biol Blood Marrow Transplant. 2011;17:1088–92. doi: 10.1016/j.bbmt.2011.01.017.
    1. Alyea EP, Weller E, Fisher DC, et al. Comparable outcome with T-cell-depleted unrelated-donor versus related-donor allogeneic bone marrow transplantation. Biol Blood Marrow Transplant. 2002;8:601–7. doi: 10.1053/bbmt.2002.v8.abbmt080601.
    1. Pavletic SZ, Carter SL, Kernan NA, et al. Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation. Blood. 2005;106:3308–13. doi: 10.1182/blood-2005-04-1614.
    1. Devine SM, Carter S, Soiffer RJ, et al. Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials network protocol 0303. Biol Blood Marrow Transplant. 2011;17:1343–51. doi: 10.1016/j.bbmt.2011.02.002.
    1. Witte T, Hoogenhout J, Pauw B, et al. Depletion of donor lymphocytes by counterflow centrifugation successfully prevents acute graft-versus-host disease in matched allogeneic marrow transplantation. Blood. 1986;67:1302–8.
    1. Urbano-Ispizua A, Brunet S, Solano C, et al. Allogeneic transplantation of CD34+-selected cells from peripheral blood in patients with myeloid malignancies in early phase: a case control comparison with unmodified peripheral blood transplantation. Bone Marrow Transplant. 2001;28:349–54. doi: 10.1038/sj.bmt.1703154.
    1. Schumm M, Lang P, Bethge W, et al. Depletion of T-cell receptor alpha/beta and CD19 positive cells from apheresis products with the CliniMACS device. Cytotherapy. 2013;15:1253–8. doi: 10.1016/j.jcyt.2013.05.014.
    1. Handgretinger R. Negative depletion of CD3(+) and TcRalphabeta(+) T cells. Curr Opin Hematol. 2012;19:434–9. doi: 10.1097/MOH.0b013e3283582340.
    1. Keever-Taylor CA, Devine SM, Soiffer RJ, et al. Characteristics of CliniMACS(R) System CD34-enriched T cell-depleted grafts in a multicenter trial for acute myeloid leukemia-Blood and Marrow Transplant Clinical Trials Network (BMT CTN) protocol 0303. Biol Blood Marrow Transplant. 2012;18:690–7. doi: 10.1016/j.bbmt.2011.08.017.
    1. Geyer MB, Ricci AM, Jacobson JS, et al. T cell depletion utilizing CD34(+) stem cell selection and CD3(+) addback from unrelated adult donors in paediatric allogeneic stem cell transplantation recipients. Br J Haematol. 2012;157:205–19. doi: 10.1111/j.1365-2141.2012.09048.x.
    1. Diamond DJ, et al. Immunohistochemical analysis of T cell phenotypes in patients with graft-versus-host disease following allogeneic bone marrow transplantation. Transplantation. 1995;59:1436–44. doi: 10.1097/00007890-199505270-00014.
    1. Salzmann-Manrique E, et al. Joint modeling of immune reconstitution posthaploindetical stem cell transplantation in pediatric patients with acute leukemia comparing CD34+ selected to CD3/CD19 depleted graft in a retrospective multicenter study. Front Immunol. 2018;9:1841. doi: 10.3389/fimmu.2018.01841.
    1. Bertaina A, et al. HLA-haploidentical stem cell transplantation after removal of αβ+ T and B cells in children with nonmalignant disorders. Blood. 2014;124:822–6. doi: 10.1182/blood-2014-03-563817.
    1. Castro-Malaspina H, Harris RE, Gajewski J, et al. Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. Blood. 2002;99:1943–51. doi: 10.1182/blood.V99.6.1943.
    1. Castro-Malaspina H, Jabubowski AA, Papadopoulos EB, et al. Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings. Biol Blood Marrow Transplant. 2008;14:458–68. doi: 10.1016/j.bbmt.2008.02.006.
    1. Small TN, Avigan D, Dupont B, et al. Immune reconstitution following T-cell depleted bone marrow transplantation: effect of age and posttransplant graft rejection prophylaxis. Biol Blood Marrow Transplant. 1997;3:65–75.
    1. Tamari R, Chung SS, Papadopoulos EB, et al. CD34-selected hematopoietic stem cell transplants conditioned with myeloablative regimens and antithymocyte globulin for advanced myelodysplastic syndrome: limited graft-versus-host disease without increased relapse. Biol Blood Marrow Transplant. 2015;21:2106–14. doi: 10.1016/j.bbmt.2015.07.010.
    1. Bayraktar UD, de Lima M, Saliba RM, et al. Ex vivo T cell-depleted versus unmodified allografts in patients with acute myeloid leukemia in first complete remission. Biol Blood Marrow Transplant. 2013;19:898–903. doi: 10.1016/j.bbmt.2013.02.018.
    1. Spitzer B, Jakubowski AA, Papadopoulos EB, et al. A chemotherapy-only regimen of busulfan, melphalan, and fludarabine, and rabbit antithymocyte globulin followed by allogeneic T-cell depleted hematopoietic stem cell transplantations for the treatment of myeloid malignancies. Biol Blood Marrow Transplant. 2017;23:2088–95. doi: 10.1016/j.bbmt.2017.07.004.
    1. Jakubowski AA, Small TN, Young JW, et al. T cell depleted stem-cell transplantation for adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulin. Blood. 2007;110:4552–9. doi: 10.1182/blood-2007-06-093880.
    1. Barba P, Hilden P, Devlin SM, et al. Ex vivo CD34(+)-selected T cell-depleted peripheral blood stem cell grafts for allogeneic hematopoietic stem cell transplantation in acute leukemia and myelodysplastic syndrome is associated with low incidence of acute and chronic graft-versus-host disease and high treatment response. Biol Blood Marrow Transplant. 2017;23:452–8. doi: 10.1016/j.bbmt.2016.12.633.
    1. Jakubowski AA, Small TN, Kernan NA, et al. T cell-depleted unrelated donor stem cell transplantation provides favorable disease-free survival for adults with hematologic malignancies. Biol Blood Marrow Transplant. 2011;17:1335–42. doi: 10.1016/j.bbmt.2011.01.005.
    1. Hobbs GS, Perales MA. Effects of T-cell depletion on allogeneic hematopoietic stem cell transplantation outcomes in AML patients. J Clin Med. 2015;4:488–503. doi: 10.3390/jcm4030488.
    1. Goldberg JD, Linker A, Kuk D, et al. T cell-depleted stem cell transplantation for adults with high-risk acute lymphoblastic leukemia: long-term survival for patients in first complete remission with a decreased risk of graft-versus-host disease. Biol Blood Marrow Transplant. 2013;19:208–13. doi: 10.1016/j.bbmt.2012.09.003.
    1. Hobbs GS, Hamdi A, Hilden PD, et al. Comparison of outcomes at two institutions of patients with ALL receiving ex vivo T-cell-depleted or unmodified allografts. Bone Marrow Transplant. 2015;50:493–8. doi: 10.1038/bmt.2014.302.
    1. Tamari R, Oran B, Hilden P, et al. Allogeneic stem cell transplantation for advanced myelodysplastic syndrome: comparison of outcomes between CD34(+) selected and unmodified hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2018;24:1079–87. doi: 10.1016/j.bbmt.2018.01.001.
    1. Barba P, Martino R, Zhou Q, et al. CD34(+) Cell selection versus reduced-intensity conditioning and unmodified grafts for allogeneic hematopoietic cell transplantation in patients age >50 years with acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant. 2018;24:964–72. doi: 10.1016/j.bbmt.2017.12.804.
    1. Malard F, Labopin M, Cho C, Blaise D, Papadopoulos EB, Passweg J, O'Reilly R, et al. Ex-vivo and in-vivo T cell-depleted allogeneic stem cell transplantation in patients with acute myeloid leukemia in first complete remission resulted in similar overall survival: on behalf of the ALWP of the EBMT and the MSKCC. J Hematol Oncol. 2018;11 doi: 10.1186/s13045-018-0668-3. 127 .
    1. Wagner JE, Thompson JS, Carter SL, Kernan NA. Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial. Lancet. 2005;366:733–41. doi: 10.1016/S0140-6736(05)66996-6.
    1. Pasquini MC, Logan B, Jones RJ, et al. Blood and marrow transplant clinical trials network report on the development of novel endpoints and selection of promising approaches for graft-versus-host disease prevention trials. Biol Blood Marrow Transplant. 2018;24:1274–80. doi: 10.1016/j.bbmt.2018.01.002.
    1. Van Heijst JW, Ceberio I, Lipuma LB, et al. Quantitative assessment of T cell repertoire recovery after hematopoietic stem cell transplantation. Nat Med. 2013;19:372–7. doi: 10.1038/nm.3100.
    1. Lewin SR, Heller G, Zhang L, et al. Direct evidence for new T-cell generation by patients after either T-cell-depleted or unmodified allogeneic hematopoietic stem cell transplantations. Blood. 2002;100:2235–42.
    1. Barba P, Roldán E, Orti G, Fox L, Salamero O, Bosch F, Valcárcel D. Resultados del trasplante alogénico vs trasplante alogénico no manipulado en pacientes con leucemia aguda y síndrome mielodisplásico; In LX Congreso Nacional SEHH XXXIV Congreso Nacional SETH; Granada, Spain. 2018. Comunicación personal.
    1. Eyrich M, Croner T, Leiler C, et al. Distinct contributions of CD4(+) and CD8(+) naive and memory T-cell subsets to overall T-cell-receptor repertoire complexity following transplantation of T-cell-depleted CD34-selected hematopoietic progenitor cells from unrelated donors. Blood. 2002;100:1915–18. doi: 10.1182/blood-2001-11-0005.
    1. Goldberg JD, Zheng J, Ratan R, et al. Early recovery of T-cell function predicts improved survival after T-cell depleted allogeneic transplant. Leuk Lymphoma. 2017;58:1859–71. doi: 10.1080/10428194.2016.1265113.
    1. Perales MA, Goldberg JD, Yuan J, et al. Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation. Blood. 2012;120:4882–91. doi: 10.1182/blood-2012-06-437236.
    1. Goldberg GL, King CG, Nejat RA, et al. Luteinizing hormone-releasing hormone enhances T cell recovery following allogeneic bone marrow transplantation. J Immunol. 2009;182:5846–54. doi: 10.4049/jimmunol.0801458.
    1. Velardi E, Tsai JJ, Holland AM, et al. Sex steroid blockade enhances thymopoiesis by modulating Notch signaling. J Exp Med. 2014;211:2341–9. doi: 10.1084/jem.20131289.
    1. Storek J, Gooley T, Witherspoon RP, Sullivan KM, Storb R. Infectious morbidity in long-term survivors of allogeneic marrow transplantation is associated with low CD4 T cell counts. Am J Hematol. 1997;54:131–8. doi: 10.1002/(SICI)1096-8652(199702)54:2<131::AID-AJH6>;2-Y.
    1. Huang YT, Neofytos D, Foldi J, et al. Cytomegalovirus Infection after CD34(+)-selected hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2016;22:1480–6. doi: 10.1016/j.bbmt.2016.05.003.
    1. Kim SJ, Huang YT, Foldi J, et al. Cytomegalovirus resistance in CD34(+) -selected hematopoietic cell transplant recipients. Transplant Infect Dis. 2018;20:e12881. doi: 10.1111/tid.12881.
    1. Huang YT, Kim SJ, Lee YJ, et al. Co-infections by double-stranded DNA viruses after ex vivo T cell-depleted, CD34(+) selected hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2017;23:1759–66. doi: 10.1016/j.bbmt.2017.06.008.
    1. Lee YJ, Chung D, Xiao K, et al. Adenovirus viremia and disease: comparison of T cell-depleted and conventional hematopoietic stem cell transplantation recipients from a single institution. Biol Blood Marrow Transplant. 2013;19:387–92. doi: 10.1016/j.bbmt.2012.10.014.
    1. Lee YJ, Huang YT, Kim SJ, et al. Adenovirus viremia in adult CD34(+) selected hematopoietic cell transplant recipients: low Incidence and high clinical impact. Biol Blood Marrow Transplant. 2016;22:174–8. doi: 10.1016/j.bbmt.2015.08.019.
    1. Marty FM, Ljungman P, Chemaly RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017;377:2433–44. doi: 10.1056/NEJMoa1706640.
    1. Hiwarkar P, Amrolia P, Sivaprakasam P, et al. Brincidofovir is highly efficacious in controlling adenoviremia in pediatric recipients of hematopoietic cell transplant. Blood. 2017;129:2033–7. doi: 10.1182/blood-2016-11-749721.
    1. Marty FM, Winston DJ, Chemaly RF, et al. A randomized, double-blind, placebo-controlled phase 3 trial of oral brincidofovir for cytomegalovirus prophylaxis in allogeneic hematopoietic-cell transplantation. Biol Blood Marrow Transplant. 2018;25:369–81. doi: 10.1016/j.bbmt.2018.09.038.
    1. O'Reilly RJ, Prockop S, Hasan AN, Koehne G, Doubrovina E. Virus-specific T-cell banks for ‘off the shelf’ adoptive therapy of refractory infections. Bone Marrow Transplant. 2016;51:1163–72. doi: 10.1038/bmt.2016.17.
    1. Tzannou I, Papadopoulou A, Naik S, et al. Off-the-shelf virus-specific T cells to treat BK virus, human herpesvirus 6, cytomegalovirus, epstein-barr virus, and adenovirus infections after allogeneic hematopoietic stem-cell transplantation. J Clin Oncol. 2017;35:3547–57. doi: 10.1200/JCO.2017.73.0655.
    1. Kosuri S, Adrianzen Herrera D, Scordo M, et al. The impact of toxicities on first-year outcomes after ex vivo CD34(+)-selected allogeneic hematopoietic cell transplantation in adults with hematologic malignancies. Biol Blood Marrow Transplant. 2017;23:2004–11. doi: 10.1016/j.bbmt.2017.07.012.
    1. Rondon-Clavo C, Scordo M, Hilden P, et al. Early fluid overload is associated with an increased risk of nonrelapse mortality after ex vivo CD34-selected allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2018;24:2517–22. doi: 10.1016/j.bbmt.2018.07.031.
    1. Cho C, Hsu M, Barba P, et al. Long-term prognosis for 1-year relapse-free survivors of CD34+ cell-selected allogeneic hematopoietic stem cell transplantation: a landmark analysis. Bone Marrow Transplant. 2017;52:1629–36. doi: 10.1038/bmt.2017.197.
    1. Armand P, Kim HT, Sainvil MM, et al. The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial. Br J Haematol. 2016;173:96–104. doi: 10.1111/bjh.13931.
    1. Pinana JL, Perez-Pitarch A, Garcia-Cadenas I, et al. A time-to-event model for acute kidney injury after reduced-intensity conditioning stem cell transplantation using a tacrolimus- and sirolimus-based graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant. 2017;23:1177–85. doi: 10.1016/j.bbmt.2017.03.035.
    1. Shah GL, Scordo M, Kosuri S, et al. Impact of toxicity on survival for older adult patients after CD34(+) selected allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2018;24:142–9. doi: 10.1016/j.bbmt.2017.08.040.
    1. Jakubowski AA, Petrlik E, Maloy M, et al. T cell depletion as an alternative approach for patients 55 years or older undergoing allogeneic stem cell transplantation as curative therapy for hematologic malignancies. Biol Blood Marrow Transplant. 2017;23:1685–94. doi: 10.1016/j.bbmt.2017.06.024.
    1. Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912–19. doi: 10.1182/blood-2005-05-2004.
    1. Barba P, Ratan R, Cho C, et al. Hematopoietic cell transplantation comorbidity index predicts outcomes in patients with acute myeloid leukemia and myelodysplastic syndromes receiving CD34(+) selected grafts for allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2017;23:67–74. doi: 10.1016/j.bbmt.2016.10.017.
    1. Dahi PB, Morawa E, Perales MA, et al. Low incidence of GvHD with T-cell depleted allografts facilitates further treatments for post-transplantation relapse in AML and MDS. Bone Marrow Transplant. 2016;51:991–3. doi: 10.1038/bmt.2016.23.
    1. Sehn LH, Alyea EP, Weller E, et al. Comparative outcomes of T-cell-depleted and non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: impact of donor lymphocyte infusion. J Clin Oncol. 1999;17:561–8. doi: 10.1200/JCO.1999.17.2.561.
    1. Perales MA, Jenq R, Goldberg JD, et al. Second-line age-adjusted International Prognostic Index in patients with advanced non-Hodgkin lymphoma after T-cell depleted allogeneic hematopoietic SCT. Bone Marrow Transplant. 2010;45:1408–16. doi: 10.1038/bmt.2009.371.
    1. Bryant A, et al. Efficacy of donor lymphocyte infusion in CD34+ allogeneic hematopoietic stem cell transplant for myeloid and lymphoid malignancies: a single center experience. Biol Blood Marrow Transplant. 2018;24:S303–4. doi: 10.1016/j.bbmt.2017.12.349.
    1. Pasquini MC, Devine S, Mendizabal A, Baden LR, Wingard JR, Lazarus HM, et al. Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transplantation. J Clin Oncol. 2012;30:3194–201. doi: 10.1200/JCO.2012.41.7071.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa